US Markets
AZN

AstraZeneca still waiting for FDA decision to resume U.S. trial-CEO

Credit: REUTERS/DADO RUVIC

AstraZeneca is still waiting for the go-ahead from the U.S. drug regulator to restart the clinical trial of its COVID-19 vaccine hopeful in the United States, Chief Executive Pascal Soriot said on Thursday.

FRANKFURT, Sept 24 (Reuters) - AstraZeneca AZN.L is still waiting for the go-ahead from the U.S. drug regulator to restart the clinical trial of its COVID-19 vaccine hopeful in the United States, Chief Executive Pascal Soriot said on Thursday.

"We are awaiting to hear their decision," Soriot told a virtual World Economic Forum discussion.

(Reporting by Ludwig Burger Editing by Caroline Copley)

((Caroline.Copley@thomsonreuters.com; +49 (0)30 2201 33584 ;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More